Peg-filgrastim versus filgrastim after autologous stem cell tranplantation: case-control study in patients with multiple myeloma and review of the literature.
We investigated the effects of a single s.c. injection of peg-filgrastim in 32 patients with multiple myeloma who underwent autologous stem cell transplantation (AuSCT) as first line treatment. For comparison, 32 myeloma patients with similar characteristics and receiving standard daily administration of filgrastim were matched. Overall, there were no statistically significant differences between peg-filgrastim and filgrastim in terms of tolerability, marrow recovery, severity of neutropenia, incidence and duration of febrile neutropenia, documented infections and transfusions. However, some favourable trends or effects in favour of peg-filgrastim were observed. This was confirmed by a review of the published papers about this topic.
Musto
Pellegrino
P
Unit of Haematology and Stem Cell Transplantation, CROB, Centro di Riferimento Oncologico di Basilicata, Strada Provinciale, 8, 85028, Rionero in Vulture (Pz), Italy. p.musto@crob.it
Scalzulli
Potito Rosario
PR
Terruzzi
Elisabetta
E
Rossini
Fausto
F
Iacopino
Pasquale
P
Messina
Giuseppe
G
Guariglia
Roberto
R
Pietrantuono
Giuseppe
G
Villani
Oreste
O
D'Auria
Fiorella
F
Falcone
Antonietta
A
Sanpaolo
Grazia
G
Valvano
Maria Rosa
MR
Pogliani
Enrico Maria
EM
Morabito
Fortunato
F
D016022:Case-Control Studies; D000069585:Filgrastim; D016179:Granulocyte Colony-Stimulating Factor / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D009101:Multiple Myeloma / Q000188:drug therapy / Q000601:surgery*; D011092:Polyethylene Glycols / Q000009:adverse effects / Q000627:therapeutic use*; D011994:Recombinant Proteins; D033581:Stem Cell Transplantation; D016896:Treatment Outcome
D011994:Recombinant Proteins; C486981:pegylated granulocyte colony-stimulating factor, human; D016179:Granulocyte Colony-Stimulating Factor; D011092:Polyethylene Glycols; D000069585:Filgrastim